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ABSTRACT
Exposure to amphetamine during early postnatal
s'

development induces long-term reductions in protein

kinase A (PKA) activity. Because PKA activity is known to

regulate the production of brain derived neurotrophic
factor (BDNF), and reductions in BDNF are associated with
memory deficits, we hypothesized that early exposure to
amphetamine would lead to declines in both BDNF levels and

memory performance. Thus in the present study, rat pups

were given daily injections of saline or amphetamine (2.5,
5, 10, or 20 mg/kg) on postnatal days 11-20 and spatial

learning was assessed using the Morris water maze on
postnatal days 28 and 29. In addition, on postnatal day 30
the striatum and hippocampus were removed and levels of

BDNF and TrkB (the BDNF receptor) were measured. Contrary
to our predictions, rats pretreated with amphetamine did
not show a decline in memory performance or have decreased

levels of BDNF or TkrB. Male rats, however, treated with
the 20 mg/kg amphetamine performed better on the water

maze task than saline-treated males or female rats
receiving the same dose. Interestingly, female rats had

higher densities of TrkB receptors in the hippocampus than
males regardless of drug treatment. In conclusion,

amphetamine pretreatment did not lead to learning or

memory deficits in adolescent rats, nor did it lead to
decreases in BDNF and TrkB levels.
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CHAPTER ONE
INTRODUCTION

Attention Deficit Hyperactivity Disorder (ADHD) is a
developmental disorder characterized by symptoms of

inattention, impulsivity, and hyperkinesias (Sagvolden &

Seargeant, 1998; Waslick & Greenhill, 1997). Furthermore,
children with ADHD are easily distracted, which leads to
decreased academic performance and impairments in learning

and memory (Waslick & Greenhill, 1997). According to the

1998 National Institutes of Health Consensus Development
Conference Statement (National Institutes of Health,

1998), an estimated 3-5% of school-aged children were

diagnosed with ADHD. More recent studies have estimated
that 7-8.7% of school-aged children meet the diagnostic
criteria for ADHD (Bloom & Cohen, 2007; Froehlich,
Lanphear, Epstein, Barbaresi, Katusic, & Kahn, 2007).

ADHD is also diagnosed in younger children with an
estimated 1-5% of preschool-aged children in the U.S.
meeting the diagnostic criteria for this disorder (Connor,

2002; Gillberg, 1986). Because most preschool-aged
children exhibit ADHD-like behaviors at some time, the

diagnosis is much more difficult to make in this age group
(Smidts & Ooosterlaan, 2007).
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Neurobiological Theories of Attention
Deficit Hyperactivity Disorder

Although the specific cause of ADHD is unknown, there
is a body of literature indicating that many of the

behavioral symptoms of ADHD have a neurobiological basis
and are related to differences in brain structure and/or

function. For example, changes in brain function resulting
from exposure to teratogens, maternal drug use, and lead

poisoning, have all been suspected as possible causes of

ADHD (Bellinger & Needleman, 1985; Brown, Coles, Smith,

Platzma, Silverstien, Erikson, & Falek, 1991; Hartsough &
Lambert, 1985; Needleman, Gunnoe, Leviton, Reed, Peresie,

Maher, & Barrett, 1979; Varley, 1984; Zametikin, Nordahl,
Gross, King, Semple, et al., 1990). In addition, there is

growing evidence that abnormalities in brain metabolism
and structure may play key roles in the manifestation of

ADHD. Using positron emission tomography, Zametikin and

colleagues (1990) found differences in brain activity
between ADHD and non-ADHD individuals. Reduced glucose
metabolism was found in many parts of the brain, including
the cingulate gyrus, right caudate, right hippocampus and

right thalamic regions. Furthermore, magnetic resonance

imaging has revealed that ADHD individuals have a smaller
splenial area of the corpus collosum than non-ADHD
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controls (Hill, Yeo, Campbell, Hart, Vigil, & Brooks,
2003) . This structural difference may indicate that there

are fewer fibers in the corpus collosum available for the

activation of frontal areas of the brain. Similarly, the
caudate, an area with many connections to the frontal

lobes, has been found to be smaller in the left hemisphere

in ADHD individuals than in controls (Filipek,
Semrud-Clikeman, Steingard, Renshaw, Kennedy, & Biederman,
1997; Hynd, Hern, Novey, Eliopulous, Marshall, Gonzalez, &

Voeller, 1993) . These differences in structure may lead to
a reduction in signaling to the frontal areas of the

brain, thus reducing motor behavior inhibition and

negatively affecting attention. This idea is further
supported by functional magnetic resonance imaging studies

that have found differences in frontal striatal circuitry,
with reduced activity in the right medial frontal cortex,
right inferior prefrontal cortex, and left caudate nucleus

of ADHD children (Castellanos, Giedd, Marsh, Hamburger,
Valtuzis, et al., 1996; Filipek et al., 1997; Scharchar,

Tannock, & Logan, 1993).
There are many theories about the cause of ADHD that
are consistent with the aforementioned structural and

metabolic abnormalities observed with ADHD. According to
one hypothesis, ADHD patients are thought to have
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under-activation of the reticular activating system
(Sagvolden & Archer, 1989). The reticular activating
system is a subcortical structure that extends from the
medulla to the midbrain region (Kelly, 1993; Reitan &

Wolfson, 1985). This structure is important for
maintaining consciousness and attentional states for the

whole brain, as the reticular activating system receives
input from most sensory systems and projects this

information throughout the central nervous system (Reitan

& Wolfson, 1985) . According to the reticular, activating

system hypothesis of ADHD, maintenance and/or direction of
attention may be impaired due to a lack of stimulation to
the higher cortical regions that mediate attention. In the

ADHD patient, the reticular activating system may filter
too much sensory information, leading to reduced signaling

to the cortex resulting in attention deficits (Klove,
1989).
Other research suggests that genetic factors may be

involved in the inattention component of ADHD. In a review
of eight molecular studies, Swanson, Flodman, Kennedy,
Spence, Moyzis, et al.

(2000) investigated the

hypothesized association between the dopamine transporter
1 gene and dopamine receptor D4 gene polymorphism and

found that the over replication of these genes may alter
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activity in the dopamine networks affecting attention. As
a result of these polymorphisms, dopamine transporter 1
may be overefficient in dopamine reuptake, while dopamine

receptor D4 may be subsensitive to dopamine. The impact of
these polymorphisms may be reduced activity in dopamine
pathways involved in attention (Swanson et al., 2000).
In summary, these theories and data imply that the
behavioral symptoms of ADHD are the result of under-active

dopamine pathways, and insufficient norepinepherine
release from the locus coeruleus. Therefore, it is

reasonable to hypothesize that psychostimulants such as
amphetamine and methylphenidate alleviate ADHD symptoms by

increasing extracellular dopamine and norepinepherine
levels in many brain areas.
Psychostimulant Treatment for Attention
Deficit Hyperactivity Disorder

In the United States, patients diagnosed with ADHD

are most often treated initially with a stimulant drug
such as methylphenidate or amphetamine (AMPH>, whereas in

Europe some form of psychosocial intervention is initially
tried (Paule, Rowland, Ferguson, Chelonis, Tannock,

Swanson, & Castellanos, 2000; Robinson, Sclar, Skaer, &

Galin, 2008). Interestingly, in a United States study
examining the management of stimulants for pediatric
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patients treated for psychological problems, psychosocial
interventions and follow-ups were infrequent. In visits
where psychostimulants were prescribed, psychosocial

intervention was included less than 50% of the time, and

in 21% of cases np recommendations for follow-up visits
were made (Hoagwood, Jensen, Feil, Vitiello, & Bhatara,

2000).

Although psychosocial interventions such as
behavioral modification have some benefits in the

treatment of ADHD (Pelham, Wheeler, & Chronis 1998),
treatment with stimulant drugs significantly improves
behavioral symptoms in 75-90% of ADHD patients (Arnold,
2000, Robinson et al., 2008). Because methylphenidate and

AMPH increase the amount of dopamine available in the
brain (During, Bean, & Roth, 1992; Castaneda, Levy, Hardy,
& Trujillo, 2000) , this finding provides further support

for the hypothesis that an insufficient amount of dopamine

may be responsible for the behavioral symptoms of ADHD

(Castaneda et al., 2000; Levy, & Hobbes, 1996).
Psychostimulant Treatment for
Preschool-Aged Children

In contrast to school-aged children, few studies have
assessed the efficacy and long-term effect of stimulant

treatment in preschool-aged children. Currently, a group
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called the Preschool Psychopharmacology Working Group is

striving toward the development of psychopharmacological
guidelines for the treatment of ADHD in preschool-aged
children (Gleason, Egger, Emslie, Greenhill, Kowatch, et

al., 2007). Despite this lack of information on the
efficacy of psychostimulant treatment, a study that
examined trends for prescribing psychotropic drugs to
preschoolers (ages 2-4) found that over a five-year period

(1991-1995) prescriptions for psychotropic drugs,

including psychostimulants, increased 3-fold (Zito, Safer,
dos Reis, Gardner, Boles, & Lynch, 2000). As the number of

preschool-aged children treated with stimulants increases,
so do the concerns over the long-term safety of its use.
In addition, manufacturers of these drugs do not recommend
their use in children under three, however, "off-label"
use is common (DSM Pharmaceuticals, 2002; Gleason et al,
2007) .

Although there is currently little evidence that

methylphenidate has any negative effects on the developing

brain, there have been many studies reporting that AMPH
drugs can produce long-term neurochemical deficits in

adult animals consistent with neurotoxicity (Hotchkiss &

Gibb, 1980; Pu & Vorhees, 1993; Ricaurte, Guillery,
Seiden, & Moore, 1982; Ricaurte, Seiden, & Schuster, 1984;
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Wagner, Ricaurte, Seiden, Schuster, Miller, & Westley,

1980). Because of these findings and current prescription
trends, it is imperative that the safety of AMPH treatment
in the developing brain be more closely examined.
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CHAPTER TWO
DOPAMINE AND ADRENERGIC SYSTEMS

It has been hypothesized that AMPH- and
methylphenidate-induced improvements in attention are

mediated by the dopamine and noradrenergic systems. The

dopamine system of the rat has two primary ascending
pathways, the nigrostriatal and mesocorticolimbic (Butler

& Hodos, 1996). The nigrostriatal system originates in the
A9 area of the substantia nigra and terminates in the

neostriatum (i.e., caudate and putamen; Butler & Hodos,

1996). The mesocorticolimbic system extends from the

ventral tegmental area to the limbic system (Butler &
Hodos, 1996). These pathways are important for the

selection, regulation and maintenance of motor functioning
(Mason, 1984). The primary noradrenergic system is the

dorsal noradrenergic bundle. This pathway originates in
the locus coeruleus and projects to the medial forebrain

bundle and limbic system (including the hippocampus,

amygdala, septum, and anterior olfactory cortex). This

system is important in mediating selective attention, the
orienting response, and vigilance (Aston-Jones & Bloom,

1981; Aston-Jones, Chiang, & Alexinsky, 1991).
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The rate of synthesis of dopamine is dependent on the

amount of tyrosine hydroxylase available in the neuron
(Walker, 1986). Extracellular tyrosine (absorbed from the
diet or synthesized from dietary phenylalanine), is
actively transported into all catecholaminergic neurons,

where tyrosine hydroxylase converts it to
3,4-dihydroxyphenylalanine (DOPA). DOPA decarboxylase then
converts DOPA to dopamine in the cytoplasm, where it is

then taken up into vesicles or granules for storage in the

nerve terminal of dopamine neurons. In noradrenergic
neurons, an additional enzyme, dopamine p-hydroxylase,

converts dopamine to norepinepherine. Interestingly,

dopamine p-hydroxylase is found in synaptic vesicles, thus
dopamine must be transported into the vesicles for
norepinepherine to be synthesized (Jasmine & Ohara, 2005).

The release of dopamine and norepinepherine occurs via

calcium dependent exocytosis and, after being released
into the synapse, these neurotransmitters can bind to

their respective receptors on the postsynaptic neuron, or
autoreceptors on the presynaptic terminal. When

autoreceptors are activated, catecholamine release and
synthesis is decreased, as tyrosine hydroxylase activity

is suppressed (Roth & Nowycky, 1977).
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All dopamine and adrenergic receptors are

metabotropic receptors (i.e., G-protein-coupled, Gingrich
& Caron, 1993; Sibley & Monsma, 1992). Dopamine receptors
are divided into two families, Di-like and D2-like, with a
total of five sub-types. The Dx-like group consists of Di
and D5 receptors, while the D2-like group contains D2, D3,
and D4 receptors (Gingrich & Caron, 1993; Sibley & Monsma,

1992). Adrenergic receptors are divided into three

families, ai, a2A and p, with a total of eight types. The

a receptors are subdivided into ai and a2 families. The ai
family consists of aiA/ <XiB, and a1D/ and the a2 family
includes a2A and

oc2b

receptors. The p family includes pi,

p2, and p3 receptors (Bylund, 1992; Rho & Storey, 2001;

U'Pritchard & Snyder, 1979).
Dopamine and norepinepherine are primarily
inactivated by active reuptake into the presynaptic

terminal through the transporter proteins DAT and NET,

respectively. In addition, metabolism by monoamine oxidase
and catechol-O-methyltransferase also inactivate these

neurotransmitters (Costa & Sandler, 1972; Walker, 1986).
The two primary dopamine metabolites produced via these

enzymatic actions are 3,4-dihydroxyphenylacetaldehyde
(DOPAC) and homovanillic acid, while the breakdown of
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norepinepherine produces several compounds, including

3-methyoxy-4-hydroxy-phenylglycol and vanillymandelic acid
(Costa & Sandler, 1972).
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CHAPTER THREE
PSYCHOSTIMULANTS

Mechanisms of Action
AMPH and methylphenidate are catecholaminergic
agonists which both increase levels of synaptic dopamine
and norepinepherine (Groves, Ryan, Young, & Fisher, 1989;

Kuczenski & Segal, 1997). Both psychostimulants rapidly
accumulate in the brain following administration (within
1-5 minutes post IV administration, or 15-30 minutes when

administered orally) , and they are equally efficacious in
alleviating behavioral symptoms of ADHD (Markowitz &

Patrick, 2001; Wargin, Kilts, Gualtieri, Ellington,

Mueller, Kraemer, & Breese, 1983). However, in spite of
their similar effects and structure (Markowitz & Patrick,

2001), these drugs do not share the same mechanisms of•
action. Methylphenidate primarily acts by blocking the
reuptake of dopamine and norepinepherine (Russell,

deVilliers, Sagvolden, Lamm, & Taljaard, 1998).. In
contrast, AMPH preferentially releases newly synthesized

dopamine and norepinepherine by reversing the action of
the dopamine and norepinepherine reuptake pumps (Kuczenski

& Segal, 1997; Shore & Dorris, 1975). In addition, AMPH is
a weak base that is thought to disrupt the intracellular
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pH gradient, thus allowing amphetamine to diffuse into the

cell where it can interact with the vesicular membrane
transporter (Sulzer, Maidment, & Rayport, 1993).
Alkalization of the vesicle then occurs and the

neurotransmitter is released into the cell, where it can
then leave thru the cell membrane (Sulzer et al., 1993);

AMPH also affects serotonergic neurons (Ricaurte,
Schuster, & Sieden, 1980) and through this mechanism

alters corticosterone secretion and growth hormone release

(Cirulli. & Laviola, 2000) .

Acute and Repeated Effects of
Amphetamine in Adult Rats
AMPH is an indirect dopamine agonist, facilitating
the release of dopamine into the synapse by reversing the

action of the presynaptic re-uptake pumps and by releasing

dopamine from storage vesicles (Kuczenski & Segal, 1997;
Shore & Dorris, 1975). Thus, acute and repeated treatment

with AMPH increases dopamine release in the striatum and
nucleus accumbens, as well as inducing other changes in
brain neurochemistry. For example, acute treatment with a
low to moderate dose (<5 mg/kg) of AMPH increases glucose

utilization in the nucleus accumbens, increases dopamine
release, and decreases DOPAC, homovanillac acid, and

glutamate concentrations (Miele, Mura, Enrico, Esposito,
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Serra, et al. 2000; Porrino, Lucignani, Dow-Edwards, &

Sokoloff, 1984; Sharp, Zetterstrom, Ljungberg, &
Ungerstedt, 1987).

In addition to the neurochemical changes induced by
AMPH, AMPH also produces dose-dependent changes in the
behavior of rats. At very low doses (<0.1 mg/kg), acute

AMPH produces little or no effects on spontaneous behavior

(Grilly & Loveland, 2001). However, a moderate dose
(~1.0 mg/kg) of AMPH increases locomotor activity, whereas,
a high dose (-5 mg/kg) produces stereotypic behaviors such

as head bobbing, sniffing, gnawing, and licking (Antoniou
& Kafetzopoulus, 1991; Porrino et al., 1984). Repeated

treatment with AMPH can also produce an augmented
behavioral response called behavioral sensitizaton (Leith
& Kuczenski, 1981, 1982). Behavioral sensitization can be

induced by as little as one drug exposure and can be
detected for months after the last amphetamine treatment

(Leith & Kuczenski, 1981, 1982).
At higher doses (e.g. 10 mg/kg every two hours for

four injections), repeated amphetamine treatment has
neurotoxic effects in rodents, including persistent

depletions in striatal dopamine, tyrosine hydroxylase

activity, striatal dopamine receptor density, and

increases in striatal astrogliosis (Hotchkiss & Gibb,
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1980; Pu & Vorhees, 1993; Ricaurte, Guillery, Seiden, &
Moore, 1982; Ricuarte, Seiden, & Schuster, 1984; Wagner et

al., 1980).
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CHAPTER FOUR
AMPHETAMINE AND MEMORY

Dopamine and norepinepherine have modulatory roles in
memory formation and function. More specifically, dopamine
is thought to be asspciated with reward expectancy, while
norepinepherine may be involved in the maintenance of

information about the goal, and the rules to achieve that
goal (Rossetti, & Carboni, 2005). Therefore, considering

the roles of dopamine and norepinepherine in memory, and
the effects of AMPH on these neurotransmitters, it is not

surprising that AMPH treatment can alter performance on

memory tasks.

In adult rats, AMPH treatment has dose-dependent
effects on memory that interact with training experience.

For example, acute treatment with AMPH within 24 hours

post-training can enhance retention on active avoidance,
passive avoidance, and discrimination tasks (Evangelista &
Isquirdo, 1971; Haycock, van Buskirk, & Gold, 1977;

Krivanek, & McGaugh, 1969). When mice were trained for

seven days on a passive avoidance task, treatment with 0.3

or 1.0 mg/kg AMPH 24 hours post-training enhanced
retention. With six days of training prior to drug

treatment, only the 1.0 mg/kg dose of AMPH enhanced

17

retention. Interestingly, when animals were trained for
only four days, a 1.0 mg/kg post-training injection

impaired memory performance (Haycock et al., 1977).

Pre-training with acute low to moderate doses

(0.5-2.0 mg/kg) of AMPH decreases latencies in
trial-dependent learning tasks, and enhances conditioned

behaviors on avoidance and discrimination tasks (Haycock

et al., 1977). Interestingly, AMPH withdrawn animals
(previously treated with escalating doses of AMPH) exhibit

enhanced performance in a water maze task and show less

interference from prior learning (Russig, Durrer, Yee,
Murphy, & Feldon, 2003).
Exposure to neurotoxic doses of AMPH can cause

lasting impairments in learning and memory. For example,
when rats are given a neurotoxic dosing regime (four

injections of 4.0 mg/kg spaced 2 hr apart), impairments
are found on an object recognition task when rats were

tested one and three weeks post drug treatment, although
no impairments in watermaze performance are observed

(Schroder, O'Dell, & Marshall, 2003). Interestingly, some
recovery occurs over time following neurotoxic AMPH

treatment in adult rats. For example, rats treated with
four 12.5 mg/kg injections of AMPH spaced 2 hr hours
apart, showed impaired performance on a spatial water maze

18

task when tested 65 days post-injection. However, animals
tested at 139 or 237 days post-injection showed no spatial

learning impairment (Friedman, Castaneda, & Hodge, 1998).
Working memory deficits occur following 1.0 mg/kg

AMPH while 0.3 mg/kg AMPH showed a trend toward improving
working and reference memory performance (Blockland,

Honig, & Prickaerts, 1998). These findings support the

idea that low doses of AMPH may enhance performance on
some learning and memory tasks, while higher doses induce
neurotoxicity and result in behavioral deficits.
Spatial Learning and Memory

Rats are animals that spontaneously explore and

investigate their environment (Renner & Seltzer, 1991).
Furthermore, these rodents are experts on spatial

)

relationships and use innate foraging patterns to search
for food when hungry (Haig, Rawlins, Olton, Mead, &
Taylor, 1983). Because of these innate behaviors, rats are

ideal subjects for the study of spatial learning and
memory, and factors affecting these processes. In a
typical spatial learning task, rats are required to use
distal spatial cues such as pictures, doors, light
fixtures, and windows to navigate and complete the task.

Spatial learning and memory are thought to be dependent on
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the integrity of the hippocampus, because rats with

lesions to this brain area have trouble learning and
remembering this type of task (Milner, Squire, & Kandel,
1998; Morris, Garrud, Rawlins, & O'Keefe, 1982; Whishaw,
1998; Wood, Dudchenko, & Eichenbaum, 1999).

Two commonly used paradigms for assessing spatial
learning and memory in rats are the radial arm maze and

the Morris water maze. In both of these mazes, animals can
use distal visuospatial cues in the room where the maze is

located to solve the maze (Hodges, 1996). In the radial
arm maze, the goal is for the animal to learn which arms

provide a food reward, without entering an arm that has no
reward (considered to be an error in working memory), and

without entering a previously visited arm (considered to
be a spatial reference memory error). The Morris water

maze is an open, circular, water tank that is conceptually
divided into four quadrants (Morris, 1981). Located in the

center of one quadrant of the maze is a submerged escape

platform, camouflaged in such a way that the animal cannot
see the platform. The task is for the animal to navigate

using distal cues to locate the hidden platform

efficiently over successive trials.

Although both mazes have been used successfully for
assessing spatial learning, working memory, and reference
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memory, the Morris water maze has a few advantages. For
example, animals do not have to be food or water deprived,
odor trails are virtually nonexistent, and motivation to

find the escape platform is very high (Hodges, 1996).

Interestingly, normal, healthy, rats quickly acquire

spatial learning tasks using either the radial arm maze or
the Morris water maze (Olton & Samuelson, 1976) .

Amphetamine and Spatial Learning
When adult rodents are administered AMPH, deficits

are often seen in spatial working and reference memory

while the animals are under the influence of the drug
(Beatty, Bierley, & Boyd, 1984; Blockland et al., 1998;
Bushnell & Levine, 1993). However, rats withdrawn from

escalating doses of AMPH show more target zone visits and
reduced latency to the former platform location during

probe trials (escape platform is removed) in the Morris
water maze (Russig et al., 2003). In addition, these

animals appeared to overcome prior learning interference
more readily than saline-treated controls during a

reversal-learning task, where the escape platform is moved
to a new location (Russig et al., 2003).

Neurotoxic dosing of methamphetamine (4 injections of

12.5 mg/kg, with 2 hr between injections) impairs spatial
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learning and memory when tested 65 days post drug
treatment. However, some recovery occurs over time, as

spatial learning and memory was not impaired at 79 and
165 days post treatment (Friedman et al., 1998).

>

Amphetamine and Brain Derived
Neurotrophic Factor

Brain derived neurotrophic factor (BDNF) is a

neurotrophic factor that is important for the growth,

survival, and maintenance of neurons, as well as for types

of synaptic plasticity such as long-term potentiation
(Bimonte-Nelson, Hunter, Nelson, & Granholm, 2003; Danzer,

Crooks, Lo, & McNamara, 2002; Mizuno, Yamada, Olariu,
Nawa, & Nabeshima, 2000). The production of BDNF occurs

through the activation of cyclic adenosine monophosphate
response element binding protein (CREB). In order for BDNF

transcription to occur, CREB must first be phosphorylated

by protein kinase A. CREB can then bind to cAMP response
element on DNA, resulting in BDNF gene transcription

(Deogracias, Espliguero, Iglesias, & Rodriguez-Pena,
2004). Interestingly, BDNF mRNA increases after training
on a radial arm maze and/or water maze (Kesslak, So, Choi,
Cotman, & Gomez-Pinilla, 1998; Mizuno at el., 2000). In

addition, if a reduction in BDNF mRNA and protein levels
is induced in the hippocampus, the formation, retention,
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and recall of spatial memory is impaired (Mizuno et al.,

2000; Mu, Li, Yao, & Zhou, 1999). BDNF and tyrosine kinase
receptor (TrkB; the receptor used by BDNF) signaling
mediates the effect of N-methyl-D-aspatate receptors in
the hippocampus. BDNF and TrkB activity promotes the

phosphorylation of N-methyl-D-aspatate receptor subunits,
enhancing receptor activity and promoting synaptic

plasticity (Levine, Crozier, Black, & Plumer, 1998).
There are a limited number of studies examining the

effects of amphetamine on BDNF mRNA or the expression of
BDNF proteins. However, in one such study, acute

amphetamine treatment (5 mg/kg, IP) in rats increased

locomotion and stereotyped behaviors, but did not affect
the basal expression of radiolabeled BDNF mRNA or protein

immunoreactivity in the forebrain (with the exception of
the piriform cortex). However, after repeated treatment

with AMPH (5 mg/kg for 5 days), stereotypy was enhanced
and BDNF mRNA immunoreactivity was elevated in the

amygdala, piriform cortex, and hypothalamus (Meredith,

Callen, & Scheuer, 2002). An increase in BDNF levels is
not surprising, because infusion with BDNF has

neuroprotective properties and can reduce neuronal death
induced by methamphetamine (Dluzen, 2004; Matsuzaki,
Namikawa, Kiyama, Mori, & Sato, 2004).
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In summary, hippocampal BDNF and TrkB are important
for spatial learning and memory, and there are limited

studies assessing the long-term effects of AMPH treatment
on BDNF expression.
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CHAPTER FIVE

DOPAMINE SYSTEM DEVELOPMENT

The development of dopamine systems in rats begins at
11-15 days of gestation with the differentiation of

dopamine neurons (Lauder & Bloom, 1974). By day 18 of
gestation in the rat, dopamine release (Normura,
Yotsumoto, & Segawa, 1981), and functional dopamine

transport mechanisms have been detected (Yotsumoto &
Nomura, 1981). At the day prior to birth, mesencephalon

dopamine levels are similar to adult levels (PND 60),
while the proencephalon dopamine levels are only 25% of

adult level. Interestingly, during the first 4-5 hours

after birth, overall brain dopamine levels decrease
dramatically, then begin to increase once again (Santana,
Rodriguez, Alfonso, & Arevalo, 1992). Dopamine levels in
the mesencephalon reach adult-like levels by PD 18, and by

four weeks of age nigrostriatal dopamine neurons show an
adult-like basal discharge rate, bursting pattern, and
conduction velocity (Pitts, Freeman, & Chiodo, 1990).
Proencephalic dopamine levels are still relatively low

during the early postnatal period, reaching only 45% of
the adult level by PD 45, and steadily increasing to

adulthood (Santana et al., 1992).

25

\

Dopamine receptor development also begins early in

prenatal development, as Di-like and D2-like receptor
binding has been seen as early as gestational day 14 (Jung

& Bennett, 1996) . Both receptor types then increase
steadily in the striatum and nucleus accumbens, with peak
receptor expression occurring at PD 28, with binding

steadily increasing until adulthood (Jung & Bennett, 1996;
Srivasta, Morency, & Mishra, 1992; Tarazi, Tomasini, &

Baldsessarini, 1998;). However, in the hippocampus peak

D2-like receptor expression does not occur until PD 35
(Jung & Bennett, 1996; Srivasta, Morency, & Mishra, 1992;

Tarazi, Tomasini, & Baldessarini, 1998).
Development of the noradrenergic system in the rat

follows a similar bi-phasic pattern. Noradrenergic neurons
have been identified as early as gestational day 12

(Morris, Dausse, Devynck, & Myer, 1980). Levels of

norepinepherine show a steady rise until the day of birth,
when levels drop dramatically, then reach adult levels by
the fifth postnatal week (Foote, Bloom, & Aston-Jones,

1983). Noradrenergic receptors also begin to develop early
and have been identified by gestational day 16, with

binding increasing to approximately adult levels at

PD 18-28. As with dopamine receptor development,
hippocampal noradrenergic receptors show peak expression
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later than other brain areas, at PD 30 (Harden, Wolfe,

Sporn, Perkins, & Molinoff, 1977; Hartley & Seeman, 1983;
Morris et al., 1980).

Behavioral Effects of Amphetamine
in Developing Rats
When AMPH is given acutely to preweanling rats or

mice, it can produce an increase in locomotor activity and
stereotyped behavior, although to a lesser degree than

seen in adult animals (Cirulli, & Laviola; 2000; Crawford,
Zavala, Karper, Collins, Loring-Meir, Watson, & McDougall,
2000; Crawford, Zavala, Karper, & McDougall, 2000, Kolta,
Scalzo, Ali, & Rolson, 1990). In addition, AMPH treatment

in developing animals results in smaller changes in

dopamine and norepinepherine than in older animals, with
0.1 mg/kg and 1.0 mg/kg AMPH producing a slight increase

,

in dopamine release, followed immediately by a significant

decrease in dopamine release (Gazzara, Fisher, & Howard,

1986; Gomes-da-Silva, deMiguel, Fernandez-Ruiz,
Summavielle, & Tavares, 2004; Lucot, Wagner, Schuster, &
Seiden, 1982).
In contrast to findings with adult animals, repeated

treatment with AMPH fails, to elicit a long-term sensitized

response in very young animals, however, AMPH can produce
a short-term sensitized response (line crosses,
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stereotyped sniffing, and vertical activity) in this age

group. For example, pups treated with 1.0, 2.5, or 5 mg/kg

AMPH for 4 consecutive days (beginning at PD 11 or PD 17)
show a sensitized response when given a challenge

injection of the same dose after two abstinence days.
However, animals that were tested following eight

abstinence days did not show a sensitized response to the
challenge injection (McDougall, Duke, Bolanos, & Crawford,
1994). Considering that the dopamine and norepinepherine

systems of rats are not fully developed at the ages used
in these experiments, the inability of these animals to
exhibit long-term sensitization may be due to the lack of

maturation in one or more brain areas.
Interestingly, immature rats do not show the same

persistent depletions in striatal dopamine, tyrosine
hydroxylase activity, and striatal dopamine receptors that

are observed in adult animals after administration of

neurotoxic doses of AMPH (Hotchkiss & Gibb, 1980; Wagner
et al., 1980; Wagner, Schuster, & Seiden, 1981). In adult

animals, prolonged depletion of striatal dopamine by
neurotoxic doses of AMPH can be prevented by prior

depletion of dopamine stores (Sieden & Schuster, 1985),
and by inhibiting dopamine uptake prior to, or shortly

after, AMPH treatment (Fuller & Hemrick-Luecke, 1980).
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This pattern of results suggests that young animals are
more resistant to AMPH-induced neurotoxic damage, perhaps
due to the immaturity of the dopamine system and an

inability to produce and release large stores of dopamine.

Long-Term Effects of Early Amphetamine Treatment

Repeated administration of AMPH in developing rats
causes long-term reductions in striatal and accumbal

protein kinase A activity persisting into adulthood

(Crawford, Zavala, Karper & McDougall, 2000). AMPH induced
reductions in protein kinase A functioning may be a cause
for concern in the developing brain, as cyclic adenosine

monophosphate dependent protein kinase A pathways are

important for many functions, including learning, memory,
reward, and addiction (Abel, Nguyen, Barad, Deuel, Kandel,

& Bourtchouladze, 1997; Beninger & Miller, 1998; Duffy &
Nguyen, 2003; Micheau & Reidel, 1999; Nestler &

Aghajanian, 1997). For example, inhibition of protein
kinase A disrupts long-lasting (or late phase) long-term

potentiation in hippocampal slices, and interferes with
memory consolidation in hippocampal dependent memories
(Abel et al., 1997; Duffy & Nguyen, 2003). In addition, it
has been suggested that protein kinase A plays an

important role in the formation of spatial memories
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(Mizuno, Yamada, Maekawa, Kuniaki, Seishima, & Nabeshima,
2002). When activated, protein kinase A phosphorylates

receptor proteins and gene transcription factors, thereby
altering the excitability of neurons (Shobe, 2001) . It has
been hypothesized that memory is formed when potassium

channels are phosphorylated and neurotransmitter release
increases (Yao & Wu, 2001).

The finding that AMPH treatment early in development
results in a long-term reduction in protein kinase A

activity is not consistent with previous studies that have
suggested that few, if any, long-term negative

consequences result from this type of treatment (Spencer,
Beiderman, Harding, O'donnell, Farone, & Willens, 1996).

It has been hypothesized that AMPH-induced reductions in
protein kinase A activity may occur as a result of changes

in dopamine receptors, specifically due to either a

downregulation or desensitization of Di-like receptors, or
as a result of an upregulation of D2~like receptors.
Furthermore, it has been found that AMPH treatment can
significantly reduce dopamine content in the striatum and

nucleus accumbens when compared to saline-treated controls

(Ricaurte et al., 1984; Fukumura, Cappon, Pu, Broeining, &

Vorhees, 1998). Examination of dopamine Di-like and
dopamine D2-like binding sites revealed that Di-like
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binding sites were unaffected by AMPH treatment, however,

a long-term increase in D2-like binding sites was found.

Interestingly, the cyclic adenosine monophosphate

dependent protein kinase A pathway is positively coupled
to Di-like receptors and negatively coupled with D2-like
receptors, thus indicating that the upregulation of

D2-like binding sites may be the mechanism by which
AMPH-induced reductions in protein kinase A activity occur
(Crawford, Zavala, Karper, Collins, Loring-Meir, Watson, &
McDougall, 2000; Crawford, Zavala., Karper, & McDougall,

2000).

Ontogeny of Spatial Memory

The development of spatial navigation and memory in

rats is associated with hippocampal functioning (Milner et
al., 1998; Morris et al., 1982; Whishaw, 1998; Wood et

al., 1999). Green and Stanton (1989) noted that

age-related differences in spatial learning tasks were
very similar to task disassociation seen with hippocampal
damage. The hippocampus of a rat grows and develops
significantly between PD 0-25. Between PD 0t16, 72% of

cells in the denate granule cell layer of the hippocampus
are generated, and between PD 11-25, 94% of synapses

appear (Altman, Brunner, & Bayer 1973). Green and Stanton
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(1989) found that rats as young as 15 days of age show

working memory, and that this capacity increases
substantially between PD 15-21. Furthermore, 20-day-old
rat pups have the capacity to learn a spatial task in the

Morris water maze, however, acquisition and retention of

this type of task is deficient when compared with mature
animals (Brown & Kraemer, 1997).

Assessing Spatial Learning and Memory
Deficits in Young Animals
Spatial learning abilities in adult animals are often

tested using the Morris water maze, however, there has
been some question as to what age young animals can be
accurately tested for learning using a water maze. Adams
and Jones (1983) used a Y maze water task to answer this

question using 18-, 20-, 22-, 28-, and 38-day-old rat
pups. They found that 28-day-old animals learned the

Y maze task better than the other groups. Significant

improvements in the ability of rats to learn the Y maze
water task occurred between 20-22 days of age. Brown and

Kraemer (1997) examined ontogenetic differences in spatial
learning using the Morris water maze, and also found that
young animals (older than 20 days) could be successfully

tested using this maze. Considering this evidence, along

with the hippocampal development data, it seems that a
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young rat can be accurately tested for spatial learning
abilities using a water maze as early as PD 25.
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CHAPTER SIX

THESIS STATEMENT
The purpose of the current study was to determine if
rat pups treated with AMPH during a critical time of

hippocampal development would exhibit deficits in spatial
learning and memory when tested in the Morris water maze

during adolescence. In addition, neurochemical assessments
were done to determine if this treatment resulted in any

long-term changes in hippocampal and striatal BDNF and

T.r.kB. We injected rat pups once per day from PD 11-20 with

saline or 2.5, 5, 10, or 20 mg/kg AMPH. These doses of
AMPH were chosen because early treatment with similar
doses decreased protein kinase A in adult rats (Crawford,
Zavala, Karper, Collins, Loring-Meir, Watson, & McDougall,

2000; Crawford, Zavala, Karper, & McDougall, 2000).

Animals were then tested beginning on PD 28-29 using the
Morris water maze hidden platform paradigm to examine

spatial learning and memory. Upon completion of behavioral
testing, TrkB immunoblotting and BDNF enzyme-linked

immunoassays were performed. All behavioral data were
recorded using a computerized video system. During the

spatial learning task, acquisition (latency to escape
platform), swim path, swim distance, and time spent in the
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quadrant where the platform was located were recorded. To
test the animal's memory of the platform location, probe

trials were conducted in which the platform was removed.
During probe trials, time spent in each quadrant, platform

site crossings, and time searching was recorded. Following
all behavioral testing, hippocampal and striatal BDNF and

TrkB levels were assessed.

It was expected animals pretreated with AMPH daily on
PD 11-17 to exhibit impairments in spatial learning and

retention in the Morris water maze task. This expected

impairment included longer latencies to the escape
platform during acquisition and less time spent searching
in the target quadrant during probe trials when compared
to saline-treated controls. In addition, it was predicted

that long-term decreases in BDNF and TrkB levels would be
seen after early AMPH treatment. This pattern of results
was anticipated because previous studies in our laboratory

have found long-term reductions in protein kinase A

activity following early AMPH treatment. Reductions in
protein kinase A activity are important because cyclic

adenosine monophosphate dependent pathways are involved in

learning and memory. In addition, protein kinase A
activity is necessary for the phosphorylation of CREB.
CREB phosphorylation regulates BDNF gene transcription,
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which is important for synaptic plasticity in learning and

memory. Therefore, these predictions were made based on
our laboratory's previous findings of reduced protein

kinase A activity and the importance of protein kinase A,
BDNF, and its receptor TrkB, in learning and memory.
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CHAPTER SEVEN
METHODS

Subjects

Subjects were 93 male and female rats (n = 8-10) of
Sprague-Dawley descent (Harlan Laboratories) born and

raised in the vivarium at California State University, San

Bernardino. The rats were housed in the vivarium which was
kept on a 12-hr light/dark cycle and maintained at

21-23°C. Rat pups were kept with dams until weaning
(PD 25), at which time they were placed in group cages

with same sex litter-mates, and remained undisturbed until
behavioral testing began. Where possible, one male and one

female pup from each litter were assigned to each drug

group in order to control for litter effects. Subjects
were treated according to the National Institute of Health

guidelines for the care and use of laboratory animals
("Principles of Laboratory Animal Care", NIH Publication

#85-23).
Drugs and Injections

AMPH was purchased from Sigma Aldrich (St. Louis).
AMPH was dissolved in saline and injected
intraperitoneally at a volume of 5 ml/kg. On PND 11-20,
rat pups were, injected once daily with 0.0, 2.5, 5, 10, or
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20 mg/kg. AMPH. Dams were removed from the litter and
placed in separate cages while pups were weighed and

injected. The dam was then returned to the home cage.
Apparatus

The Morris water maze consisted of a 122 cm diameter
black water tank with a removable transparent platform
that was located in one quadrant of the tank during

acquisition. Duripg the probe trials the platform' was
removed. The platform size was 14 cm x 14 cm, and was

1.5-2.0 cm below the surface of the water to conceal its

location. Throughout behavioral testing water temperature
was kept at 21° ± 1°C.

Pre-Training

Testing began on PND 28 with three pre-training

trials. These trials were performed to assess whether the
early drug treatment had an effect on swimming ability. In

the pre-training trials, a straight swimming channel was

placed in the tank. On each trial the rats were placed in
the water at one end of the channel and their time to

reach a visible platform at the other end of the channel
was recorded. When the rat reached the platform it was

left on the platform for 15 s before being removed and
placed in a heated holding cage for two min.
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Acquisition Training

Immediately following pre-training, acquisition

trials began. The straight channel was removed and the
black platform was placed 1.5-2.0 cm below the surface of
the water to obscure its location in the middle of one

quadrant in the tank. Start positions were randomly varied
among four cardinal start positions along the perimeter,

with each animal starting from each position once per day.

Rats were placed in the water maze and released facing the
wall at the designated starting position for that

particular animal. On PD 28 and PD 29, each animal was
given two blocks of four trials per day, with 3-4 hr

separating blocks. Between blocks, rats were dried and
returned to their home cages. In each trial, rats were
required to locate the hidden escape platform within the

60 s trial. When the animal reached the platform it
remained there for 15 s before being placed in a heated

holding cage for the remainder of the 2 min intertrial
interval. If the rat failed to find the hidden platform in

60 s, it was placed upon the platform for 15 s, then
returned to the holding cage for the remainder of the

intertrial interval. After each animal's last trial of the
day (on both testing days), rats performed a 1 min probe

trial in which the hidden platform was removed. The rat
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was placed in the Morris water maze at a designated start

point and allowed to search for one min.
Using a video tracking system (Ethno Vision, Noldus

Information Technology), swim paths, latency to reach the

hidden platform, swim distance and swim speed were
recorded during acquisition. For probe trials, time in the
quadrant where the platform was previously located, swim

distance, and swim speed were recorded.

Tissue Preparation

On the day following behavioral testing,

(i.e.,

PD 30, rats were rapidly decapitated and their hippocampus
and striatum were removed. The tissue samples for each

animal were divided into two sections and frozen at -80 °C

until time of assay.
Brain Derived Neurotrophic Factor
Enzyme-Linked Immunoassay

BDNF levels in the hippocampus and striatum were
examined using the Promega BDNF Emax Immunoassay System
(Promega, Madison, WI). Briefly, striatal and hippocampal

tissue were homongenized in distilled water and sonicated
for 15 s. Samples were then centrifuged at 16,000 * g for

30 min and resulting supernantant collected. Standard
96-well flat-bottomed Corning ELISA plates were incubated
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with carbonate coating buffer containing monoclonal
anti-BDNF overnight at 4 °C. The following day, the plates

were washed three times with TBST buffer. Standard

dilutions of BDNF ranging from 0 to 500 pg were performed
in duplicate. One hundred pl of the standard dilutions and
the tissue samples were added to each well in duplicate
and then washed five times with TBST wash buffer. The

wells were then incubated with a secondary anti-human BDNF

polyclonal antibody (1:500) for 2 h without shaking at
room temperature. Plates were washed five times with TBST

buffer. Anti-lg Y hoseradish peroxidase conjugate (1:500)
was then added to each well and plates were incubated for

1 h with shaking at room temperature. Plates were again
washed five times with TBST wash buffer. Finally, plates
were developed using 100 pl Promega TMB One Solution and
the reaction was stopped at 10 min using 100 pl N HCL.

Protein concentrations were determined using the Bio-Rad
Protien Assay (Bio-Rad Laboratories, Hercules, CA) based

on the method of Bradford (1976), using bovine serum
albumin (BSA) as a standard. BDNF levels were reported as
ng/mg tissue.
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Tyrosine Kinase Receptor (TrkB)
Immunoblotting Assay

Hippocampal and striatal homogenates (30 pg/protein)
were mixed with 25 pg sample buffer [62.5 mM Tris-HCL

(pH 6.8), 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.1% w/v
bromophenol blue]), boiled for 5 min, centrifuged, and

loaded on 15% polyacryamide gels. Rainbow-stained

molecular weight markers (Bio-Rad Laboratories) were
loaded on each gel. Gels were electrophoresed at 200 V for
2 h. Proteins were transferred to a PVDF membrane
(Immuno-Blot, Bio-Rad laboratories) and blocked for 1 h in

a solution of 5% nonfat dry milk in Tris-buffered saline
with 0.1% Tween-20. Blots were incubated overnight at room

temperature with the primary antibody anti-TrkB (Santa
Cruz Biotechnology, Santa Cruz, CA) at a dilution of

1:1,000. Blots were then washed three times for 10 min in
wash buffer (Tris-buffered saline, with 0.1% Tween-20) and
incubated in goat anti-rabbit horseradish
peroxidase-linked IgG (1:10,000; Pierce Biotechnology,
Rockford IL) for 1 h at room temperature. Following this
incubation, membranes were washed three times in wash

buffer for 10 min and then incubated briefly in
peroxidase-chemiluminescence substrate (Super Signal West,
Pierce Biotechnology). Immunoreactive bands were
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visualized using film-based autoradiography and quantified
using a computer-assisted densitometer (model GS-700,

Bio-Rad Laboratories). Protein loading and transfer were
controlled by stripping (Restore™, Pierce Biotechnology),
reblocking, and then reprobing .the membranes with a

monoclonal antibody to glyceraldehydes 3-phosphate
dehydrogenase (GAPDH; Imgenex, San Diego, CA, USA) at a

dilution of 1:20,000. Each sample was assayed in duplicate

and-matched controls were run on each gel.
Statistical Analysis

Behavioral data, including latency to escape
platform, time spent in target quadrant, swim speed and

distance traveled were assessed using separate 5x4x2

(drug x block x sex) repeated measures ANOVAs for
acquisition trials, and separate 5x2x2
(drug dose x trial x sex) ANOVA's for the probe trials.

For the TrkB and BDNF neurochemical assays, separate

ANOVAs were used to determine differences between groups.
Post hoc analysis were made using Tukey tests (p < 0.05).
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CHAPTER EIGHT

RESULTS

Weight Data

All rats were weighed on injection days (PD 11-20)
and on the first test day (PD 28). On PD 11, 12, and 13,

there were no significant differences in mean body weight

between groups. However, as treatment continued animals

receiving 10 or 20 mg/kg AMPH had a lower mean weight than
saline animals. Specifically, on PD 14-20, rats receiving
20 mg/kg had a lower mean body weight than the saline

group, while those treated with 10 mg/kg had a lower mean

body weight than saline animals on PD 16, 18, 19, and 20
[day x drug interaction: F(36,495) = 11.83, p < 0.001,
Tukey Test, p < .05, see Figure 1].
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a Significantly different from saline controls
Data in this figure are collapsed across sex.
Figure 1. Mean Body Weight (Grams) for Male and Female

Rats Treated with Saline or Amphetamine (2.5, 5.0, 10.0,
or 20.0 mg/kg) from PD 11-20

On the first test day (PD 28) animals previously

treated with 20 mg/kg still had a lower mean body weight
than saline pretreated animals [drug main effect.:

F(l,55) = 4.36, p < 0.01, Tukey Test, p < 0.05, see Figure
2], whereas the 10 mg/kg group were no longer different
than saline animals. In addition, males had higher mean

body weight than females on PD 28 [sex main effect:
F(l,56) = 18.84, p < 0.001].
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AMPH Pretreatment Dose (mg/kg)

a Significantly different from saline controls
Males had significantly higher mean body weights than
similarly treated females (main effect of sex)__________
Figure 2. Mean Body Weight (Grams) on PD 28 for Male and
Female Rats Pretreated with Saline or Amphetamine (2.5,

5.0, 10.0, or 20.0 mg/kg) from PD 11-28

Water Maze Acquisition
All animals swam successfully and located the visible

platform during the pretraining session.

For all groups, latency to reach the hidden platform
decreased with each training block regardless of drug

treatment or sex [block main effect: F(3,252) = 106.32,
p < .05, Tukey Test, p < .05, see Figure 3], indicating
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that all groups learned the task in a similar fashion. In
addition, swim distance decreased with each block

regardless of drug treatment or sex [block main effect:
F(3,249) = 103.19, p < .05, see Figure 4].

a Significantly different from block 1.
Data in this figure are collapsed across sex.
Figure 3. Mean Latency (s) to Locate the Escape Platform
Across the Four Acquisition Training Blocks for Male and
Female Rats Pretreated with Saline or Amphetamine (2.5,

5.0, 10.0, or 20.0 mg/kg) from PD 11-20
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a Significantly different from block 1.
Data in this figure are collapsed across sex._____________
Figure 4. Mean Distance Traveled (cm) to Locate the Escape
Platform Across the Four Acquisition Training Blocks for

Male and Female Rats Pretreated with Saline or Amphetamine

(2.5, 5.0, 10.0, or 20.0 mg/kg) from PD 11-20

Water Maze Probe Trials

On the probe trials, the high dose of AMPH (20 mg/kg)
significantly altered performance, but only in male rats.

Specifically, male rats treated with 20 mg/kg AMPH spent
more time, searching in the target quadrant (the quadrant
where the platform had been located previously) than
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similarly treated female rats or saline-treated male rats

[sex x drug interaction: F(4,83) = 3.72, p < .01, Tukey
Test, p < 0.05., see Figure 5]
There was also a significant difference in mean swim
velocity between male and female rats, with males swimming
faster than females on probe trial 1, but not on probe

trial 2 [sex x trial interaction: F(l,81) = 5.86, p < .05,

see Figures 6 & 7]. In addition, on probe trial 1 males

swam farther than females regardless of drug group, but on
probe trial 2 this difference was no longer present

[trial x sex interaction: F(4,83) = 8.78, p < .01, see
Figures 8 & 9].
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Probe Trials

AMPH Pretreatment Dose (mg/kg)

a Significantly different from saline controls
b Significantly different from females receiving 20 mg/kg AMPH
Figure 5. Mean Duration in Platform Quadrant(s) across
Probe Trials for Male and Female Rats Pretreated with

Saline or Amphetamine (2.5, 5.0, 10.0, or 20.0 mg/kg) from

PD 11-20
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Probe Trials

a Significantly different than males in probe trial 1
Data in this figure are collapsed across amphetamine
treatment condition.
Figure 7. Mean Swim Velocity (cm/s) during Probe Trials
for Male and Female Rats Pretreated with Saline or

Amphetamine (2.5, 5.0, 10.0, or 20.0 mg/kg) from PD 11-20
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Figure 8. Mean Swim Distance on Probe Trials One and Two
for Male and Female Rats Pretreated with Saline and

Amphetamine (2.5, 5.0, 10.0, or 20.0 mg/kg) from PD 11-20
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Figure 9. Mean Swim Distance (cm/s) during Probe Trials

for Male and Female Rats Pretreated with Saline or

Amphetamine (2.5, 5.0, 10.0, or 20.0 mg/kg) from PD 11-20

Tyrosine Kinase Receptor (TrkB) and
Brain Derived Neurotropic Factor
Contrary to expectations, when BDNF levels in the
striatum and hippocampus were analyzed, no differences

between drug treatments or sexes were found. However, when
TrkB expression was examined it was found that females had

higher densities of TrkB in the hippocampus than males

regardless of drug treatment [sex main effect:
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F(l,54) = 5.32, p < .05, see Figures 10 & 1.1] . In the
striatum, there were no significant differences in TrkB

densities between sexes or drug groups.
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Figure 10. Mean Optical Density (± SEM) of Hippocampal and
Striatal Tyrosine Kinase Receptor (TrkB) Expression in

Male and Female Rats Pretreated with Saline or Amphetamine

(2.5, 5.0, 10.0, or 20.0 mg/kg) on PD 11-20
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TrkB Expression

Brain Area
a Significantly different from TrkB expression in the
hippocampus of male rats.
Data in this figure are collapsed across amphetamine
treatment condition.______________________________________
Figure 11. Mean Optical Density (± SEM) of Hippocampal and
Striatal Tyrosine Kinase Receptor (TrkB) Expression in

Male and Female Rats Pretreated with Saline or Amphetamine

(2.5, 5.0, 10.0, or 20.0 mg/kg) on PD 11-20 (Collapsed)
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CHAPTER NINE
DISCUSSION
Early postnatal exposures to amphetamine and

amphetamine analogues have long-lasting neurochemical and
behavioral effects in adult rats (Crawford, Choi, Kohutek,
Yoshida, & McDougall, 2004; Vorhees, Inman-Wood, Morford,

Broeing, Fukumura, & Moran, 2000; Vorhees, Skelton,
Williams, 2007; Williams, Morford, Wood, Wallace,
Fukumura, Broening, & Vorhees, 2003). Interestingly, it is
unknown whether these amphetamine-induced alterations are

detectable during other stages of development. Thus, the

purpose of the present study was to determine if exposure
to AMPH during early postnatal development would alter the

behavior and neurochemistry of adolescent rats.

Specifically, we treated male and female rat pups from
PD 11 to PD 20 with saline or AMPH (2.5, 5.0, 10, or
20 mg/kg) and tested their performance using the Morris
water-maze on PD 28 and PD 29. In addition, we measured

hippocampal and striatal BDNF levels and TrkB expression.
Based on past research we had the following three

predictions concerning this study:

(1) Animals pretreated

with AMPH will exhibit impairments in spatial learning and
retention in the Morris water maze,
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(2) AMPH pretreated

animals will show decreased levels of BDNF compared to
saline controls,

(3) AMPH pretreated animals will show

decreases in TrkB expression compared to saline treated
controls.
Effects of Early Amphetamine Treatment
on Spatial Learning and Memory

Contrary to what was expected, animals pretreated
with AMPH did not have performance deficits in the Morris
water maze. During the acquisition phase, the saline and

all drug groups (2.5, 5.0, 10.0 and 20 mg/kg AMPH) learned
the task in a similar fashion, with no differences between

groups in latency to reach the hidden platform. This is
copsistent with previous findings in young rats that
indicate few, if any, long-term negative consequences

resulting from amphetamine treatment (Hotchkiss & Gibb,
1980; Spencer et al., 1996; Wagner et al., 1980).

Moreover, during the probe trials male rats

pretreated with 20 mg/kg AMPH spent more time searching in
the quadrant where the platform was previously located

than females receiving the same dose. Males treated with

20 mg/kg AMPH also spent more time searching in the

platform quadrant than saline-pretreated controls. This

finding was in opposition of our original hypothesis that
a high dose of AMPH would impair performance and instead
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suggests that pretreatment with 20 mg/kg AMPH can enhance

spatial memory, but only in male rats.
One factor that may have contributed to the
divergence in probe trial performance is differences in

spatial learning strategies used by male and female rats.

Previous studies have demonstrated male advantages in
spatial learning tasks depending on the paradigm, with

males performing better than females when spatial cues and
release points are varied (Roof & Stein, 1999). For
example, on each of 10 testing days male and female rats

were given two trials, with the hidden platform placed in

a new, random position each day. Each animal performed an
initial trial, followed one hour later by another trial.
On the second trial, sex differences were not seen if the

release point remained constant. However, if the release

point was varied on the subsequent trial, male rats
performed better. They also found that female rats could

perform as well as males with varied release points as

long as the spatial cues in the room remained constant,
suggesting that there are differences in the types of

spatial cues used by male and female rats (Roof & Stein,
1999). In the current study, it is possible that the type

of spatial cues and the movement of the experimenter (a

major cue that did not remain constant) were slightly
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better suited for male rats as opposed to female rats. Sex
differences have also been seen in a study that examined
the effects of prior non-spatial training in the Morris

water maze on the acquisition and retention of a spatial

test in the maze (Perrot-Sinal, Kostenuik, Ossenkopp, &

Kavaliers, 1996). Prior non-spatial training in the maze

improved acquisition and retention of the spatial task in
both sexes. However, in animals that did not receive prior

conditioning, males showed better acquisition and
retention of the spatial task than females (Perrot-Sinol

et al., 1996).
Gondal hormones are an additional factor that may be

important to consider regarding sex differences in spatial
learning. In a study using meadow voles, male advantages
(shorter latencies to find the hidden platform) in spatial

learning were found using the Morris water maze (Galea,
Kavaliers, Ossenkopp, & Hampson, 1995). Male voles,

regardless of current testosterone levels, showed superior
spatial learning compared to females with high estradiol
levels. This finding suggests that high estradiol levels

in female voles may impair performance on this type of
spatial task. In contrast, other studies have indicated
that high estradiol levels are beneficial on memory

because estradiol provides female rats with
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neuroprotection from toxic or ischemic insults. Thus,
females are less affected than males following chronic

stress or chronic AMPH treatment when tested on visual and

spatial memory tasks (Bisagno, Bowman, & Luine, 2003;
Sandstrom & Rowan, 2007). Although, the above studies do

not explain the dose dependent male advantage seen in this

study, gender specific spatial learning strategies such as
the ability of male rats to navigate a spatial task when

some cues are inconsistent, and differences in gonadal
hormone levels may have contributed to these findings.
Interestingly, in adult animals, repeated low doses

of AMPH (0.3 mg/kg) may enhance memory on a spatial task,
while a higher dose (1.0 mg/kg) impairs spatial memory

performance (Blockland et al., 1998). These findings

support the idea that prior exposure to low doses of AMPH
may enhance performance on some learning and memory tasks
and increase dendritic branching (Li, Kolb, & Robinson,

2003; Robinson, & Kolb, 1997) in adult animals, while
higher doses may induce deficits. In addition, it is

possible that in young animals, high doses of amphetamine
act in a way similar to low doses in adults. This may be
due to the immaturity of the dopamine system in young

animals. In adults, prolonged depletion of striatal
dopamine by neurotoxic doses of methamphetamine can be
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prevented by prior depletion of dopamine stores (Sieden &
Schuster, 1985) or by inhibiting dopamine uptake prior to
or shortly after treatment (Fuller & Hemrick-Luecke,

1980). Young animals given amphetamine early in
development (PD 11-21) may not have large stores of

dopamine to release, as much of the dopamine system is
still developing (Santana et al., 1992).
An alternative explanation for the performance of

male rats pretreated with 20 mg/kg AMPH in the water maze,

is that the increased duration of time spent in the target
quadrant on the probe trials is indicative of a kind of

cognitive impairment called perseveration. Perseveration
is a cognitive deficit where a response is repeated even

though the response is no longer appropriate. While the
majority of researchers use increased time in the quadrant
that formerly contained the platform as a measure of

learning, other researchers have demonstrated that

increased time searching in the target quadrant can be a

sign of impairment (Hodges, Veizovic, Bray, French, Rashid
et al., 2000; Obernier, White, Swartzwelder, Crews, 2002;
Van der Zee, Lourenssen, Stanisz, & Diamond, 1995).

In the present study, it is possible that amphetamine
pretreatment induced increased activity or sensitivity of
dopamine D2 receptors that lead to perseverative
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responding. The basis of this suggestion is that:

1) treatment with quinpirole,(a dopamine 02
agonist)induces perseveration (Ulloa, Nicolini, &

Fernandez-Guasti., 2004); 2) decreases in dopamine content
lead to increased perseveration (Pioli, Meissner, Sohr,

Gross, Bezard, & Bioulac, 2008); and 3) early amphetamine

treatment decreases dopamine content and causes an
upregulation of dopamine D2 receptors (Crawford, Zavala,
Karper & McDougall, 2000). Additional experiments using

different learning task will be necessary to determine
whether the increased time in the target quadrant found in
the present investigation is the result of increased

memory or indicative of cognitive dysfunction.
Effects of Early Amphetamine Treatment on Brain
Derived Neurotropic Factor and Tyrosine
Kinase Receptor (TrkB) Levels

It was predicted that animals pretreated with AMPH
would have a lower density of TrkB and BDNF in the
hippocampus and striatum than saline treated animals. This
prediction was based on previous finding in our laboratory

showing that repeated AMPH treatment reduces protein
kinase A activity (Crawford, Zavala, Karper, Collins,
Loring-Meir, Watson, & McDougall, 2000; Crawford, Zavala,

Karper, & McDougall, 2000 Crawford, Choi, Kohutek,
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Yoshida, & McDougall, 2004). Protein kinase A is necessary
for the phosphorylation of CREB, which regulates BDNF gene

transcription (Deogracias et al., 2004). However, no
changes in TrkB or BDNF were induced as a result of drug
treatment. Surprisingly, all females in this study,
regardless of drug treatment, were found to have elevated

TrkB levels compared to males.

BDNF and TrkB activity promotes the phosphorylation

of N-methyl-D-aspertate receptor subunits, enhancing
receptor activity and promoting synaptic plasticity
(Levine et al., 1998). Infusion with BDNF can also have

neuroprotective properties and can reduce neuronal death
induced by neurotoxins such as methamphetamine and

cystocine arabinoside in vitro (Dluzen, 2004; Matsuzaki et

al., 2004; Leeds, Leng, Chalecka-Franaszek & Chuang,

2005) . For example, BDNF and TrkB levels are increased
24 hours following pretreatment with diethyldithiocarb, a
neurotoxic compound that induces apoptic cell death
(Micheli, Bova, Laurenzi, Bazzucchi, & Grassi Zucconi,

2006) . Furthermore, if TrkB receptor activation is
inhibited, the neuroprotective actions of BDNF are
attenuated (Leeds et al., 2005). Considering the findings
of these past studies, it may not be surprising that

female rats were unaffected by AMPH exposure in the
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present study. Specifically, because female rats had a

higher density of TrKB receptors they may have had more

protection against AMPH-induced changes.
The cause for the sex difference in TrkB expression

is unknown but may be the result of different levels of
circulating estrogens. Other studies have shown a positive
relationship between estrogen and BDNF levels in female

rats. For example, estrogen replacement in ovariectomized
young adult female rats increases BDNF in the hippocampus,

cortex, amygdala, and septum (Allen & McCarson, 2005;

Signh, Meyer, & Simpkins, 1995; Zhou, Zang, Cohen, &
Pandey, 2005). No studies have examined whether estrogen
increases BDNF during the preweanling period, however

female rats do have larger serum levels of estradiol than
male rats on PD 1-21 (Banu, Govindarajulu, & Aruldhas,

2002). In opposition to this hypothesis, however, estrogen
treatment in castrated and intact male rat pups (ages

PD 4-PD 25) does not affect the expression of TrkB mRNA
and protein in the CAI and CA3 regions of the hippocampus

(Sugiyama, Kanba, & Arita, 2003). Unfortunately, this
study did not include female rats.
The present study was the first to examine the effect
of AMPH on spatial memory and BDNF and TrkB levels during

early postnatal development. We predicted that AMPH would
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disrupt water maze performance because repeated AMPH

(2.5 mg/kg) treatment during the preweanling period

induces a long-term decrease in protein kinase A in adult

rats (Crawford, Zavala, Karper, Collins, Loring-Meir,
Watson, & McDougall, 2000; Crawford, Zavala, Karper, &
McDougall, 2000). As mentioned earlier, protein kinase A

activity is positively related to BDNF levels and. TrkB
activity (Deogracias et al., 2004) and reductions in
protein kinase A activity can interfere with memory
consolidation (Abel et al., 1997; Duffy & Nguyen, 2003;

Mizuno et al., 2002). For example, inhibition of protein
kinase A activity decreases up-regulation of BDNF mRNA and

interferes with the consolidation of a fear memory (Ou &
Gean, 2007). In the current study, 2.5, 5.0, 10.0 and

20.0 mg/kg AMPH wepe administered during the same early
postnatal period as the Crawford, Zavala, Karper, Collins,

Loring-Meir, Watson, and McDougall (2000) and Crawford,
Zavala, Karper, and McDougall (2000) studies, therefore it
is likely that protein kinase A activity decreases

occurred in these rats as well. However, in the current

study protein kinase A was not measured, therefore it is
unclear if the changes seen in the two aforementioned

studies were present at 30 days of age, or if the deficits
in protein kinase A activity take longer to manifest. If
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decreases in protein kinase A activity did occur in the

current study, the reduction may not have been enough to
induce changes in BDNF, TrkB, or water maze performance.

implications and Conclusions
The current study supports the idea that low doses of

AMPH for the treatment of ADHD in young children are

relatively safe, as there were no neurochemical deficits
found, and behavioral changes were only seen at the

highest dose used (20 mg/kg). This dose is much higher
than what is recommended in a clinical setting. The
American Association of Child and Adolescent Psychiatry

Work Group on Quality Issues (2007) developed parameters
for the assessment and treatment of children with ADHD,

and noted that the maximum dose per day for children 3-5

years old approved by the United States Federal Drug

Administration is 40 mg/day (that would be approximately
1.8 mg/kg for a 22 kg child) for Adderall and Dexedrine
(American Association of Child and Adolescent Psychiatry

Work Group on Quality Issues, 2007), much less than the
highest dose used in this study. The recommended starting
dose for both of these drugs is only 2.5 mg/kg once or

twice daily, and side effects associated with these drugs
are most often mild and transient (Ahmann, Theye, Berg,
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Linquist, Van Erem, & Campbell, 2001). Considering that
the behavioral symptoms of ADHD can be alleviated by

psychostimulant treatment in 75-90% of ADHD patients
(Arnold, 2000, Robinson et al., 2008), the benefits of

ADHD treatment with these drugs appears to outweigh the
risks. However, further investigation of the mechanisms of
action and long-term safety of stimulant drugs is still

needed, especially for younger patients.
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